Anastasia Asimakopoulou - Search Results

Year	Number of Results
2014	2
2015	1
2016	2
2017	2
2018	1
2019	2
2020	3
2022	0

1

Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy.

Asimakopoulou A, Weiskirchen S, Weiskirchen R. Asimakopoulou A, et al. Front Physiol. 2016 Sep 27;7:430. doi: 10.3389/fphys.2016.00430. eCollection 2016. Front Physiol. 2016. PMID: 27729871 Free PMC article. Review.

2

TNF-α controls Lipocalin-2 expression in PC-3 prostate cancer cells.

Schröder SK, Asimakopoulou A, Tillmann S, Koschmieder S, Weiskirchen R. Schröder SK, et al. Among authors: asimakopoulou a. Cytokine. 2020 Nov;135:155214. doi: 10.1016/j.cyto.2020.155214. Epub 2020 Jul 24. Cytokine. 2020. PMID: 32712458

3

Perilipin 5 and Lipocalin 2 Expression in Hepatocellular Carcinoma.

Asimakopoulou A, Vucur M, Luedde T, Schneiders S, Kalampoka S, Weiss TS, Weiskirchen R. Asimakopoulou A, et al. Cancers (Basel). 2019 Mar 19;11(3):385. doi: 10.3390/cancers11030385. Cancers (Basel). 2019. PMID: 30893876 Free PMC article.

4

Lipocalin-2 (NGAL/LCN2), a "help-me" signal in organ inflammation.

Asimakopoulou A, Borkham-Kamphorst E, Tacke F, Weiskirchen R. Asimakopoulou A, et al. Hepatology. 2016 Feb;63(2):669-71. doi: 10.1002/hep.27930. Epub 2015 Jul 31. Hepatology. 2016. PMID: 26054053 No abstract available.

5

Targeting Activated Hepatic Stellate Cells Using Collagen-Binding Chitosan Nanoparticles for siRNA Delivery to Fibrotic Livers.

Azzam M, El Safy S, Abdelgelil SA, Weiskirchen R, Asimakopoulou A, de Lorenzi F, Lammers T, Mansour S, Tammam S. Azzam M, et al. Among authors: asimakopoulou a. Pharmaceutics. 2020 Jun 25;12(6):590. doi: 10.3390/pharmaceutics12060590. Pharmaceutics. 2020. PMID: 32630415 Free PMC article.

6

Deletion of Perilipin 5 Protects Against Hepatic Injury in Nonalcoholic Fatty Liver Disease via Missing Inflammasome Activation.

Asimakopoulou A, Engel KM, Gassler N, Bracht T, Sitek B, Buhl EM, Kalampoka S, Pinoé-Schmidt M, van Helden J, Schiller J, Weiskirchen R. Asimakopoulou A, et al. Cells. 2020 May 28;9(6):1346. doi: 10.3390/cells9061346. Cells. 2020. PMID: 32481590 Free PMC article.

7

Altered mitochondrial and peroxisomal integrity in lipocalin-2-deficient mice with hepatic steatosis.

Asimakopoulou A, Fülöp A, Borkham-Kamphorst E, de Leur EV, Gassler N, Berger T, Beine B, Meyer HE, Mak TW, Hopf C, Henkel C, Weiskirchen R. Asimakopoulou A, et al. Biochim Biophys Acta Mol Basis Dis. 2017 Sep;1863(9):2093-2110. doi: 10.1016/j.bbadis.2017.04.006. Epub 2017 Apr 7. Biochim Biophys Acta Mol Basis Dis. 2017. PMID: 28396286 Free article.

8

Data on Lipocalin 2 and phosphatidylinositol 3-kinase signaling in a methionine- and choline-deficient model of non-alcoholic steatohepatitis.

Asimakopoulou A, Borkham-Kamphorst E, de Leur EV, Weiskirchen R. Asimakopoulou A, et al. Data Brief. 2017 Jul 1;13:644-649. doi: 10.1016/j.dib.2017.06.048. eCollection 2017 Aug. Data Brief. 2017. PMID: 28725667 Free PMC article.

9

Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.

Hassan R, Tammam SN, Safy SE, Abdel-Halim M, Asimakopoulou A, Weiskirchen R, Mansour S. Hassan R, et al. Among authors: asimakopoulou a. Eur J Pharm Biopharm. 2019 Jan;134:96-106. doi: 10.1016/j.ejpb.2018.11.018. Epub 2018 Nov 22. Eur J Pharm Biopharm. 2019. PMID: 30471341

10

Lipocalin-2 (LCN2) regulates PLIN5 expression and intracellular lipid droplet formation in the liver.

Asimakopoulou A, Borkham-Kamphorst E, Henning M, Yagmur E, Gassler N, Liedtke C, Berger T, Mak TW, Weiskirchen R. Asimakopoulou A, et al. Biochim Biophys Acta. 2014 Oct;1842(10):1513-24. doi: 10.1016/j.bbalip.2014.07.017. Epub 2014 Jul 31. Biochim Biophys Acta. 2014. PMID: 25086218

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results